{
  "slug": "mdd-serotonin",
  "round": 2,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "reviewer": "Claude Opus 5.5 (Anthropic)",
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "reinforcing / stabilizing factor",
  "role_after": "reinforcing / stabilizing factor",
  "pmids_checked": 21,
  "pmids_failed": 0,
  "claims_spot_checked": 11,
  "validator": "PASS (34 checks, 0 FAIL, 0 WARN)",
  "findings": [
    {
      "id": "S-1",
      "severity": "Major",
      "location": "Consensus provenance reconciliation - 9 October 2026",
      "original": "The earlier adversarial approval refers to its original edition",
      "corrected": "No earlier adversarial approval exists for this case",
      "evidence": "no approval section/banner/line for this slug anywhere in deliverables; regression introduced by the Oct 9 revision",
      "type": "false_approval_reference"
    },
    {
      "id": "S-2",
      "severity": "Minor",
      "location": "Evidence inventory SC2; claim register C11; scorecard evidence entries",
      "original": "a separate synthesis of 131 trials in 27,422 participants found -1.94 HDRS points",
      "corrected": "pooled estimate attributed to the 49 of those 131 trials reporting the outcome",
      "evidence": "PMID 28178949 abstract: 131 trials / 27,422 participants included; mean difference -1.94 HDRS (95% CI -2.50 to -1.37) from 49 trials. Load-bearing for SC2's clinical-significance finding; magnitude and CI unchanged",
      "type": "analysis_set_misattribution"
    },
    {
      "id": "S-3",
      "severity": "Editorial",
      "location": "Evidence inventory SC2",
      "original": "1.80 HRSD points in the complete FDA registration dataset",
      "corrected": "...for the four new-generation antidepressants with full data (35 trials, 5,133 patients)",
      "evidence": "PMID 18303940 analysed FDA licensing trials of four new-generation antidepressants with full datasets; the review's own C10 and score card already carry the precise scope",
      "type": "scope_imprecision"
    }
  ],
  "rejected_findings": [
    {
      "item": "antidepressant-efficacy statements",
      "reason": "Cipriani, Jakobsen and the Cochrane active-placebo review all reported exactly, including primary outcomes and the authors' own conclusions; no ITT/per-protocol claim is made; lay summary states the grade is not a claim that antidepressants do not work"
    },
    {
      "item": "serotonin-deficiency statements",
      "reason": "umbrella review, critique and reply reported as positions; depletion strata reproduced exactly; never-depressed null used to block Delta, not as support"
    },
    {
      "item": "confidence band",
      "reason": "rationale already rests on evidence density and reproducibility with no appeal to access depth; Moderate stands under the 2026-10-14 lead policy; no rewrite needed"
    },
    {
      "item": "weakest-link aggregation / headline",
      "reason": "pre-registered for the conjunctive form; derivation correct; SC4's higher level reported separately"
    },
    {
      "item": "Best-supported rival renderer artifact",
      "reason": "rank 1 is neuroinflammation, a non-nominal model; the nominal ranks 2 of 5"
    },
    {
      "item": "momentum / stability values",
      "reason": "both carry the required artifact; no 'Decisive work underway' claim"
    },
    {
      "item": "REVIEWER NOTES vs spliced Consensus section",
      "reason": "no 'no Consensus work' claim; the three cited artifacts exist and the four historical identifiers resolve to on-topic records"
    },
    {
      "item": "reference [16] year 2025 vs PubMed 2024",
      "reason": "plus-or-minus-one print/e-pub convention"
    },
    {
      "item": "rendering defects",
      "reason": "none present (no glued numerals, no empty DOI fields, no PMIDnot strings)"
    }
  ],
  "propagate_to": [],
  "divergent_copies": [],
  "approval": "Approved as revised"
}